AI assistant
Sending…
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2021
Jun 8, 2021
7082_dirs_2021-06-08_f3f04cff-4fd7-42f5-8695-678c5a14c3a5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2021-06-05
Reporting Person: Elstein Amir (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-05 | Ordinary Shares | M | 6041 | — | Acquired | 2030266 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-05 | Restricted Share Units | $ | M | 6041 | Disposed | Ordinary Shares (6041) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on June 5, 2018 and vested on June 5, 2021.